Gyre Therapeutics Inc. (GYRE) — Capital Reinvestment Ratio

Latest as of March 2026: 0.06x

Gyre Therapeutics Inc. (GYRE) has a Capital Reinvestment Ratio of 0.06x as of March 2026, meaning it reinvests 0% of its operating cash flow ($3.18 Million) in capital expenditures ($178.00K). Check Gyre Therapeutics Inc. (GYRE) tangible net worth to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.06x
Capex / Operating Cash Flow

Operating Cash Flow

$3.18 Million
USD

Capital Expenditures

$178.00K
USD

Data as of

Mar 2026
Most recent filing

Gyre Therapeutics Inc. Capital Reinvestment Ratio (2007–2025)

This chart tracks Gyre Therapeutics Inc.'s Capital Reinvestment Ratio across 5 annual periods. For the full cash flow conversion analysis, see Gyre Therapeutics Inc. (GYRE) cash flow conversion.

Annual Capital Reinvestment Ratio for Gyre Therapeutics Inc. (2007–2025)

Year-by-year Capital Reinvestment Ratio for Gyre Therapeutics Inc. from 2007 to 2025. See Gyre Therapeutics Inc. free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2025 1.18x $1.01 Million $1.19 Million ▲ +255.3%
2023 0.33x $25.89 Million $8.59 Million ▼ -29.2%
2022 0.47x $10.68 Million $5.00 Million ▲ +1855.3%
2010 0.02x $138.30 Million $3.31 Million ▼ -88.0%
2007 0.20x $24.84 Million $4.94 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow